Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial

Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial

ABSTRACT Background Studies indicated that afatinib combined with angiogenesis inhibitor may achieve promising efficacy in non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Methods This is a multicenter, Phase II trial to explore the efficacy and saf...

Full description

Saved in:
Bibliographic Details
Main Authors: Huiyang Shi, Miaohan Wang, Junling Li, Shi Jin, Minglei Zhuo, Jun Zhao, Hongxia Zhang, Meng Yang, Qingfang Shi, Haifeng Qin, Guilan Dong, Dongmei Lan, Zhong Dai, Yu Feng, Haohua Zhu, Jingyu Lu, Kai Zhu, Yuankai Shi, Xingsheng Hu
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Thoracic Cancer
Subjects:
afatinib plus bevacizumab
epidermal growth factor receptor mutations
first‐line treatment
non‐small cell lung cancer
pleural metastasis
Online Access:https://doi.org/10.1111/1759-7714.70137
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/1759-7714.70137

Similar Items